EDIT vs BEAM
EDIT and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $417.74M | $2.39B |
| P/B | — | 2.24 |
| P/S | 10.3x | 17.1x |
| Revenue | — | $156.03M(TTM) |
| Revenue growth (YoY) | 25.4% | 120.0% |
| Net income | — | -$86.52M(TTM) |
| Earnings growth (YoY) | 32.5% | 78.8% |
| EPS, diluted | — | $-0.69(TTM) |
| EBIT margin | -394.9% | -274.6% |
| ROE | -152.0% | -7.5% |
| ROIC | — | -40.5% |
| 1y total return | -3.9% | +0.9% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: EDIT vs BEAM
| 지표 | EDIT | BEAM |
|---|---|---|
| 최종 가치 | $966 | $12.3K |
| 총수익률 | -90.3% | +23.2% |
| CAGR | -29.8% | +3.2% |
| 변동성 | 92.4% | 79.8% |
| 샤프 | 0.01 | 0.38 |
| 소르티노 | 0.02 | 0.59 |
| 최대 낙폭 | -98.9% | -89.1% |
공통 거래일 1661일 기준, 2020-02-06 → 2026-09-16 · 무위험수익률 4.11% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)